




University of California
San Francisco



The Future of Diagnostic Tools in AFM

Charles Chiu, MD / PhD


Professor, Department of Laboratory Medicine and Medicine / Infectious Diseases

Director, UCSF-Abbott Viral Diagnostics and Discovery Center

Associate Director, UCSF Clinical Microbiology Laboratory

University of California, San Francisco

AFM Virtual Symposium, June 19th, 2020




AFM Etiology?

- No infectious agents of clinical significance identified in CSF
 - *including metagenomic next-generation sequencing*
- No poliovirus in CSF, stool, rectal samples
- No WNV or other arboviruses detected
- In 2014 and 2016, EV-D68 most common pathogen detected from non-sterile sites (primarily respiratory)

Is EV-D68 a Cause of AFM?

Number of confirmed U.S. AFM cases reported to CDC by month of onset,

August 2014 - March 2019^{^*†}




Diagnostic Tools in Microbiology

- Culture
- Nucleic Acid Testing (e.g. PCR)
- MALDI (matrix-assisted laser desorption ionization) spectrometry
- Electron Microscopy (rarely used)
- Antigen Testing
- Metagenomic Sequencing
- Serology (Antibody Testing)
- Host Response Biomarkers

Diagnostic Tools in Microbiology (Infectious Causes of AFM)

- Culture – *not done for routine diagnostics*
- Nucleic Acid Testing (e.g. PCR) / CRISPR-based detection – *diagnosis in acute phase (>7 days); respiratory secretions and stool, not CSF*
- MALDI – *bacterial/fungal detection only*
- Electron Microscopy – *not used for routine diagnostics*
- Antigen Testing – *unexplored area, includes metabolomics*
- Metagenomic Sequencing – *rule out other causes?*
- Serology (Antibody Testing) – *utility for CSF or serum (?)*
- Host Response Biomarkers – *may allow detection in “window period”*


AFM Reported Cases-2020



Thus far in 2020, there have been 9 confirmed cases in 6 states and the District of Columbia.

<https://www.cdc.gov/acute-flaccid-myelitis/cases-in-us.html>

AFM Reported Cases-2018



In 2018, there were 238 total confirmed cases in 42 states. One of the confirmed cases is a foreign resident (based on the country of usual residence) and therefore not included in the state map.

<https://www.cdc.gov/acute-flaccid-myelitis/cases-in-us.html>

Enterovirus Detection in CSF, Respiratory, Stool samples

Vital Signs: Surveillance for Acute Flaccid Myelitis — United States, 2018

Weekly / July 12, 2019 / 68(27);608–614

TABLE 2. Laboratory results from cerebrospinal fluid (CSF), respiratory, and stool specimens collected from patients with confirmed acute flaccid myelitis (N = 233) — United States, 2018

Specimen source	No. with specimens available (% of 233)	No. (%) positive	Positive test results (No.)
CSF	74 (32)	2/74 (3)	EV-A71 (1) EV-D68 (1)
Respiratory	123 (53)	54/123 (44)	EV-D68 (30) EV-A71 (10) Other/Untyped EV/RV (14)
Stool	100 (43)	13/100 (13)	EV-D68 (1) EV-A71 (2) Echovirus 11 (1) Coxsackievirus (3) Parechovirus (4) Other/Untyped EV/RV (2)

Abbreviations: EV = enterovirus; RV = rhinovirus.

Multiplexed Viral PCR Testing Cannot Discriminate Rhinoviruses from Enteroviruses



FilmArray target	No. (%) of specimens		
	With target	Confirmed EV-D68 positive	EV-D68 negative
Human rhinovirus 1,4	22	20 (41)	2 (5)
Human rhinovirus 1,2,4	19	17 (34)	2 (5)
Human rhinovirus 4	13	7 (15)	6 (15)
Human rhinovirus 1,2,3,4	27	5 (10)	22 (55)
Human rhinovirus 3,4	4	0 (0)	4 (10)
Human rhinovirus 1,2	2	0 (0)	2 (5)
Human rhinovirus 1	1	0 (0)	1 (2.5)
Human rhinovirus 2,4	1	0 (0)	1 (2.5)
Enterovirus 1	0	0 (0)	0 (0)
Enterovirus 2	0	0 (0)	0 (0)
Total	89	49 (100)	40 (100)

Organism (abbreviation)	Classification (Genome type)	Season of Highest Incidence ^a	Most Commonly Infected Demographic
Adenovirus (AdV)	Adenovirus (DNA)	Late winter to early summer ^[1]	All ages, immunocompromised ^[1]
Coronavirus (CoV) 229E, HKU1, NL63, OC43	Coronavirus (RNA)	Winter, spring ^[2-3]	Children, adults ^[2-3]
Enterovirus (EV)	Picornavirus(RNA)	Summer, early fall ^[4]	All ages ^[5]
Human Rhinovirus (HRV)	Picornavirus (RNA)	Fall, spring ^[6]	All ages ^[6]
Human Metapneumovirus (hMPV)	Paramyxovirus (RNA)	Winter, early spring ^[7]	Children ^[7]
Influenza A (Flu A) (subtypes H1, H1-2009, and H3)	Orthomyxovirus (RNA)	Winter ^[8]	All ages ^[8] , 5-20 % of US population ^[9]
Influenza B (Flu B)	Orthomyxovirus (RNA)	Winter ^[8]	All ages ^[8] , 5-20 % of US population ^[9]
Parainfluenza Virus 1 (PIV1)	Paramyxovirus (RNA)	Fall, periodicity of 1-2 years ^[10]	Infants, young children, immunocompromised ^[10]
Parainfluenza Virus 2 (PIV2)	Paramyxovirus (RNA)	Fall, periodicity of 1-2 years ^[10]	Infants, young children, immunocompromised ^[10]
Parainfluenza Virus 3 (PIV3)	Paramyxovirus (RNA)	Spring, summer ^[10]	Infants, young children, immunocompromised ^[10]
Parainfluenza Virus 4 (PIV4)	Paramyxovirus (RNA)	Unknown	All ages ^[11]
Respiratory Syncytial Virus (RSV)	Paramyxovirus (RNA)	Winter, varies by location ^[12-13]	Children, older adults ^[12-13]
<i>Bordetella pertussis</i>	Bacterium (DNA)	No peak season	All ages ^[14]
<i>Chlamydomphila pneumoniae</i>	Bacterium (DNA)	No peak season	Older children, young adults, immunocompromised ^[15]
<i>Mycoplasma pneumoniae</i>	Bacterium (DNA)	Outbreaks most common in summer, outbreak periodicity 4 – 7 years	Older children, young adults ^[16-17]



CRISPR–Cas12-based detection of SARS-CoV-2

James P. Broughton^{1,7}, Xianding Deng^{2,3,7}, Guixia Yu^{2,3}, Clare L. Fasching¹, Venice Servellita^{2,3}, Jasmeet Singh¹, Xin Miao¹, Jessica A. Streithorst², Andrea Granados^{2,3}, Alicia Sotomayor-Gonzalez^{2,3}, Kelsey Zorn⁴, Allan Gopez², Elaine Hsu², Wei Gu², Steve Miller², Chao-Yang Pan⁵, Hugo Guevara⁵, Debra A. Wadford⁵, Janice S. Chen¹✉ and Charles Y. Chiu^{2,3,6}✉


An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR–Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from patients in the United States, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections. Our CRISPR-based DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement.

COVID-19 in the United States, on 28 February 2020, the US Food and Drug Administration (FDA) permitted individual clinically licensed laboratories to report the results of in-house-developed SARS-CoV-2 diagnostic assays while awaiting results of an EUA submission for approval⁸.

Here we report the development and initial validation of a CRISPR–Cas12-based assay^{9–13} for detection of SARS-CoV-2 from extracted patient sample RNA, called SARS-CoV-2 DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR). This assay performs simultaneous reverse transcription and isothermal amplification using loop-mediated amplification (RT-LAMP)¹⁴ for RNA extracted from nasopharyngeal or oropharyngeal swabs in universal transport medium (UTM), followed by Cas12 detection of predefined coronavirus sequences, after which cleavage of a reporter molecule confirms detection of the virus. We first designed primers targeting the E (envelope) and N (nucleocapsid) genes of


(collaboration with Mammoth Biosciences, Inc.)

CRISPR-Based Diagnostics



- diagnosis of infectious disease
- emerging pathogen surveillance
- viral genotyping
- antibiotic or antiviral resistance
- SNP identification
- companion diagnostic (+ treatment)
- cancer screening

A CRISPR Based Test for SARS-CoV-2



	CDC qRT-PCR positive	CDC qRT-PCR negative
DETECTR positive or presumptive positive	38	0
DETECTR negative	2	42
	PPA: (38 of 40 = 95%)	NPA: (42 of 42 = 100%)

N gene RNA

+
-



Control Test
↓ ↓



(Broughton, et al., 2020, Nature Biotechnology, DOI: [10.1038/s41587-020-0513-4](https://doi.org/10.1038/s41587-020-0513-4))

Clinical Validation and Next Steps

**5-min lysis and
95C heat
inactivation**



LoD: 20 copies/mL

Sensitivity: 27/29 = 93%

Specificity: 100%

(Servellita, et al., 2020, manuscript in preparation)

Metagenomic Sequencing



Clinical Laboratory



Metagenomic Next-Generation
Sequencing



Bioinformatics



**Clinical
Dx**




Lower healthcare costs

Improved patient outcomes



Cost-effective and actionable information for
early treatment

Turnaround time: hours – days (versus days – weeks)



ATTACGCC
ATACTGCATG
TCGATCGTAC
TAGACTAGCA
TCGAAACG

GAAACGCG
CACGCGATCGA
GATCGCGAGACT
AGCTACGTACGTCA
AGATCGCGATCT
CTAGCGACCAT
ATGCATA

ACG
CTAT
CACTAGC
GGCTCG
CCCCCTATATT
GTTT
SCA

CG
TCGATCGAGCT
GCGAGACTCGA
TACGTACGTCAGTCA
ATCGCGATCTAGAG
AGCGACCATCG
AAGCATACGTAGC
AGCTCGA

GTACGT
AGCATCGTCC
GCATACGCAT
GCGATCTAGA
GATCGATCG
CCCCTATAT
ACCATCGAT
TATCTCGCG
GTTTACAACCAACTAG
TGCATACGTACGCATACTGCATG
CTCAGTCAGCATCGATCATTAGGCG
AGCATCAGCGTAACGATCGGCATCGAT
CTGCGATCGATCGATCGTACTGACTG
ACTCTATCGTCACATGAGCTAGCTAC
GCGCGCTATAGCGCATCTAACGTCAG
CCGATAGCTAGACTAGCATCACTAGC
ATACGCGCGACTACGCGATCAGATCGC
ATATCTCTATTTTAGGCGCGCTAGCGAT
GATCGGATCGAAACGCGGCTGAGCCC
GCGCGAGCGGAACCCGCGCTGACCA
CGCGCGCATCAGATAGCGCGATATA
AGCGGCCACGCGATCGAGCTATTACA
ATCACTACTCAGTACGCATGCACGTAC
TGACAGTACGACTGACTCAGCAGCA
AGGCTCGCGAGACTCGAGCATAGCGT
CATCGTTCGATGCTGACTAGCTGCTCG
ACTGAGCTATGCTATGCTGACTCTCGT
CTAGCGGTACGTCAGTCACGCGCTAT
AACGTCATCGTTCGTCAATCCGAGAGCT
TCAATACGCATCAGCATACGCGCGA
CGATCTAGACGTCATATCTCTAT
ATCGATCGATAGCGATCGGATC
CCCTATATTAGAGCGCGCTG
CATCGATCTTACGCGCTATCTCGCG
ATCTCGCGGATAGCGGATACCAAC
AACCAACAGCGATCAACGCAT
ACGCATATGCATGAT

SCG
ACGTACG
GATCGCG
TAGCGAG
ATGCAT
AG
CA
AT
CG
CGT

GCATG
ATCGTACTG
GACTAGCAT
GAAACGCC
GCGAT

CLIA-Validated mNGS Assay at UCSF



[For Providers](#) [For Patients](#) [Technology](#) [Our Vision](#)

Our Diagnostic Lab

Only at UCSF: the next generation of diagnostic tests.

The **UCSF Clinical Microbiology Laboratory** offers a validated test for diagnosis of meningitis /encephalitis from cerebrospinal fluid in our CLIA-certified laboratory. Results are interpreted by laboratory physicians, and consultation services are available upon request.

<http://nextgendiagnosics.ucsf.ed>

Case Report from Cleveland Clinic

- 70 y/o male with mild dementia x 1 year
- Over past month, rapid decline until he became akinetic and mute
- No inflammatory changes on MRI or in CSF but fever x 3 weeks
- Treated with IV solumedrol and plasmapheresis
- Negative autoimmune encephalitis workup
- History of non-Hodgkin's lymphoma s/p chemotherapy, last cycle 2-3 years ago, also treated with Rituxumab
- From a rural area but not very active

mNGS239 JT 200508

Sequencing

SURPI+ files

Heat maps

Krona plots



Select data:

NT snap matched d16 fl Viruses filt NTblastn_tru dust species clx ▾

Size: ☐ ☐ ☒ ☐

Selected sequences: 0

Download Fasta

Download SAM

Blast NCBI

- 0 +

Color scale: ☒ log₂ ☐ actual

Coloring:

Sort by: ☒ value ☐ taxa

Value: count ▾

Filter taxa: ☐ Type pathogen

Subtract taxa: ☒ Host bacteria ☒ Host plants

Subtr:

Accession: All ▾


Prep: ☐ DNA ☒ RNA

Batch: ☒ A200506

Retroviridae	Lentivirus	Human immunodeficiency virus 1
Retroviridae	Lentivirus	*
Retroviridae	Lentivirus	Simian immunodeficiency virus
Retroviridae	Lentivirus	Human immunodeficiency virus
Flaviviridae	Pegivirus	GB virus C
Papillomaviridae	Nupapillomavirus	Nupapillomavirus 1
Retroviridae	Gammaretrovirus	Murine leukemia virus
Papillomaviridae	Betapapillomavirus	Betapapillomavirus 1
Herpesviridae	Cytomegalovirus	Human herpesvirus 5
Papillomaviridae	-	Human papillomavirus

Retroviridae	Lentivirus	Simian-Human immunodeficiency virus
Bunyaviridae	Orthobunyavirus	Bunyamwera virus
Retroviridae	Gammaretrovirus	*
Retroviridae	-	Citrus endogenous pararetrovirus
Retroviridae	Gammaretrovirus	Murine leukemia-related retroviruses
Poxviridae	Molluscipoxvirus	Molluscum contagiosum virus
Papillomaviridae	Betapapillomavirus	Betapapillomavirus 2
Anelloviridae	-	Torque teno virus

NGS_239_3614
NGS_239_3615
NGS_239_3616
NGS_239_3617
NGS_239_3618
NGS_239_3619
NGS_239_3620
NGS_239_3621
NGS_239_3622
NGS_239_3623
NGS_239_3624



Analytical_RNA	rep
count	15
cell reads	15 100.0%
sample reads	65 23.1%
species reads	15 100.0%
total reads	264042 0.0%

[Blast NCBI nt](#)

0 1

4

18

mNGS239 JT 200508

Sequencing

SURPI+ files

Heat maps

Krona plots



Select file:

Orthobunyavirus Bunyamwera_virus 17225332 species ▾

Series:



Coverage



Percent identity

Shading:




min/max

Bunyamwera virus (gi|17225332|, 943 bp)

Bunyamwera virus segment S, complete sequence

Assembled from 15 reads; displaying actual values.



Toggle Log/Linear Y-axis

Download Consensus

Reset Zoom

Save PDF

	Reference length bp	Coverage in bp	Percent coverage	Avg coverage depth	Covered pct ident
Overall	943	272	28.84	0.63	32.35
Displayed	943	272	28.84	0.63	32.35

Job Title	15 sequences (SNL170:596:HFWTGBCX3:1:1103:14783:76991#A)		
RID	BH133W2C014	Search expires on 05-12 06:46 am	Download All ▼
Results for	1:lcl Query_39805 SNL170:596:HFWTGBCX3:1:1103:14783:76991#ATGCGCAG+CT ... ▼		
Program	BLASTN ? Citation ▼		
Database	nt See details ▼		
Query ID	lcl Query_39805		
Description	SNL170:596:HFWTGBCX3:1:1103:14783:76991#ATGCGCAG+CT ...		
Molecule type	dna		
Query Length	106		
Other reports	Distance tree of results ?		

Filter Results

Organism
only top 20 will appear
☐ exclude

+ Add organism

Percent Identity

to

E value

to

Query Coverage

to

Filter
Reset

- Descriptions

Graphic Summary

Alignments

Taxonomy

Sequences producing significant alignments

Download ▼ Manage Columns ▼ Show 100 ▼ ?

☒ select all 16 sequences selected

[GenBank](#) [Graphics](#) [Distance tree of results](#)

	Description	Max Score	Total Score	Query Cover	E value	Per. Ident	Accession
☒	Potosi virus strain 89-3380 segment S, complete sequence	185	185	100%	2e-43	98.11%	MH484323.1
☒	Potosi virus strain 89-3380 segment S, complete sequence	185	185	100%	2e-43	98.11%	NC_043647.1
☒	Potosi virus nucleocapsid (N) and small non-structural protein (NSs) genes, complete cds	185	185	100%	2e-43	98.11%	AY729652.1
☒	Maguari virus strain CoAr 3363 segment S, complete sequence	132	132	89%	3e-27	91.58%	KX100106.1
☒	Cache Valley virus isolate CVV-078 nucleoprotein and NSs protein genes, complete cds	132	132	89%	3e-27	91.58%	GU018034.1
☒	Cache Valley virus isolate CVV-002 nucleoprotein and NSs protein genes, complete cds	132	132	89%	3e-27	91.58%	GU018033.1
☒	Cache Valley virus isolate R103016b segment S, complete sequence	126	126	89%	2e-25	90.53%	MK861965.1
☒	Cache Valley virus strain MNZ-92011 nucleoprotein and NSs protein genes, complete cds	126	126	89%	2e-25	90.53%	KC436108.1
☒	Cache Valley virus isolate CVV-390 nucleoprotein and NSs protein genes, complete cds	126	126	89%	2e-25	90.53%	GU018036.1

Potosi virus

- Orthobunyavirus first isolated from *Aedes albopictus* mosquitoes in Potosi, MO, in 1989
- Subsequent isolations in Illinois, Michigan, Ohio, and the Carolinas, northeastern United States (Armstrong, et al., *J Med Entol*, 2005, 42(5): 875-881)
- Never described in human illness
- Close relative, Cache Valley virus recently described in case reports of chronic meningoencephalitis in patients with SCID and on Rituxamab (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546801/>, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037180/>)



AMERICAN
SOCIETY FOR
MICROBIOLOGY



AN OPEN ACCESS JOURNAL PUBLISHED BY
THE AMERICAN SOCIETY FOR MICROBIOLOGY

Serology (Antibody Testing)

mBio. 2019 Jul-Aug; 10(4): e01903-19.


Published online 2019 Aug 13. doi: [10.1128/mBio.01903-19](https://doi.org/10.1128/mBio.01903-19)

PMCID: PMC6692520

PMID: [31409689](https://pubmed.ncbi.nlm.nih.gov/31409689/)



Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis

Nischay Mishra,^{#a} Terry Fei Fan Ng,^{#b} Rachel L. Marine,^b Komal Jain,^a James Ng,^a Riddhi Thakkar,^a Adrian Caciula,^a Adam Price,^a Joel A. Garcia,^a Jane C. Burns,^c Kiran T. Thakur,^d Kimbell L. Hetzler,^e Janell A. Routh,^b Jennifer L. Konopka-Anstadt,^b W. Allan Nix,^b Rafal Tokarz,^a Thomas Briesse,^a M. Steven Oberste,^{#b} and W. Ian Lipkin^{✉#a}



Mishra, et al., mBio, 2019, 10(4): e01903-19.

Pan-Serological Approaches for Diagnosis of Infections using Phage Display Immunoprecipitation and Sequencing



Michael
Wilson,
MD




Joseph
DeRisi,
PhD

Enterovirus Immunoreactivity in Acute Flaccid Myelitis




Ryan
Schubert,
MD




Michael
Wilson,
MD

Schubert, et al., 2019, *Nature Medicine*, 25(11):1748-1752.



The “Window Period” of Infection



Host-Based RNA-Seq Classifier


(Viral Meningitis Versus
Enterovirus-Associated AFM)

Based on 185 differentially expressed genes
Only includes AFM for which a virus was
found


- Misclassified samples:
- MNA_362: Enterovirus B
 - MNA_384: CMV
 - MNA_426: CMV
 - MNC_311: WNV
 - MNA_228: WNV

Out of 45 viral samples, 18 AFM samples:

Sensitivity = 100%
Specificity = 88.8%



CSF Host Response Profiling Discriminates Enterovirus Signatures in Acute Flaccid Myelitis



Top Differentially Expressed Pathways in EV-D68-associated AFM

negative regulation of cell fate commitment

spinal cord association neuron differentiation

negative regulation of cell differentiation

negative regulation of cell fate specification

negative regulation of neurogenesis

negative regulation of gastrulation

negative regulation of nervous system development

dorsal spinal cord development

negative regulation of multicellular organismal process

negative regulation of developmental process

negative regulation of cell development

positive regulation of endoplasmic reticulum calcium ion concentration

regulation of transcription involved in primary germ layer cell fate commitment

negative regulation of neuron differentiation

regulation of gene expression

regulation of cell fate commitment

regulation of cell fate specification

positive regulation of neural precursor cell proliferation

olfactory pit development

dorsal/ventral pattern formation

epithelial cell differentiation

neurogenesis


negative regulation of necrotic cell death

central nervous system neuron differentiation

EV-A71-associated AFM



- ~50% returned to neurologic baseline by discharge
- All but one child with AFM had complete recovery of strength with normal neurologic exam at most recent follow-up



Initially reported in Messacar, K., et al. (2018). "Notes from the Field: Enterovirus A71 Neurologic Disease in Children - Colorado, 2018." MMWR Morb Mortal Wkly Rep 67(36): 1017-1018.
Updated with final case counts (unpublished, under review)

(slide courtesy of Dr. Kevin Messacar)

Differentially Expressed Genes Between EV-D68 and EV-A71 Infection

Initial pathway analysis:

Negative Regulation of Viral Entry into host cell

Response to Interferon-alpha

Type I interferon signaling pathway

Primary neural tube formation

Innate immune response- activating signal transduction




A71 – D68 Classifier (training set)


1 Missed call:

GY_AFP2014_15 (D68) -> A71


(90% accuracy)



A71 – D68 Classifier (training set)



A71 – D68 Classifier (test set)



A71 – D68 Classifier (test set)

Neural Net Model

D68: 3/4 = 75%

A71 AFM: 3/3

A71 Meningitis: 7/9 = 77.7%

Overall Accuracy: 13/16 = 81.25%

<u>D68:</u>	Predicted	Prob. D68	Prob. A71
GY_AFP2014_12	D68	0.8114	0.1886
GY_AFP2014_10	A71	0.2651	0.7349
GY_AFP2014_13	D68	0.5183	0.4817
GY_AFP2014_16	D68	0.8114	0.1886

<u>A71:</u>	Predicted	Prob. D68	Prob. A71
MNC_2194	A71	0.2651	0.7349
AMES162	A71	0.2651	0.7349
AMES152	A71	0.338	0.662

<u>A71 meningitis:</u>	Predicted	Prob. D68	Prob. A71
MNC-2846	D68	0.5221	0.4779
MNC-2899	A71	0.2651	0.7349
AMES145	A71	0.2651	0.7349
AMES149	A71	0.2651	0.7349
AMES150	D68	0.5192	0.4808
AMES151	A71	0.2651	0.7349
AMES155	A71	0.2651	0.7349
AMES156	A71	0.2651	0.7349
AMES157	A71	0.2651	0.7349

Conclusions

- **Diagnostic testing for AFM is challenging**
 - *diagnosis is currently based on a clinical case definition*
- **PCR testing alone is likely insufficient**
 - *Negative testing from CSF*
 - *Cannot discriminate rhinoviruses from enteroviruses*
 - *Difficult to routinely test early in the disease course*
- **Indirect testing methods are needed**
 - *CSF antibody testing and “host response” testing during the window period of infection*
- **Timely diagnosis is critically important**
 - *more aggressive interventions may be indicated if diagnosis of EV-D68 can be made earlier*

Looking at the host genes in AFM



Priya Duggal, PhD, MPH.

*Associate Professor, Department of
Epidemiology*

*Director, Genetic Epidemiology Track
Johns Hopkins Bloomberg School of Public
Health*